Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.47
-0.0100-0.40%
Post-market: 2.45-0.0200-0.81%19:58 EDT
Volume:4.71M
Turnover:11.52M
Market Cap:2.11B
PE:-3.99
High:2.50
Open:2.47
Low:2.39
Close:2.48
Loading ...

Exploring High Growth Tech Stocks in the United States

Simply Wall St.
·
29 Jan

ImmunityBio Says EMA Accepts Marketing Application for Anktiva

MT Newswires Live
·
27 Jan

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Jan

Immunitybio Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anktiva® for the Treatment of Patients With Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

THOMSON REUTERS
·
27 Jan

Stock Track | ImmunityBio Soars Over 5% in Pre-Market on Plans for Multiple FDA Submissions in 2025

Stock Track
·
17 Jan

Stock Track | ImmunityBio Soars 7.57% on Plans for Multiple FDA Submissions in 2025

Stock Track
·
17 Jan

Why ImmunityBio, Inc. (IBRX) Is Skyrocketing

Insider Monkey
·
17 Jan

ImmunityBio Shares Jump After Cancer Pipeline, Drug Application Updates

MT Newswires Live
·
17 Jan

ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances

Dow Jones
·
17 Jan

J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug

Zacks
·
16 Jan

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
16 Jan

BRIEF-ImmunityBio Provides Regulatory Update On Anticipated FDA Submissions In 2025 Following Meeting With The Agency

Reuters
·
16 Jan

Immunitybio Provides Regulatory Update on Global Submission for Anktiva + Bcg in Bcg Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in Europe and United Kingdom

THOMSON REUTERS
·
16 Jan

Immunitybio: to Submit Bla in 2025 for Second- & Third-Line Treatment of Patients With Nsclc Progressing on Checkpoint Inhibitors

THOMSON REUTERS
·
16 Jan

Immunitybio: Preparing to Submit Sbla in 2025 for Nmibc Bcg Unresponsive Papillary Disease

THOMSON REUTERS
·
16 Jan

Immunitybio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting With the Agency

THOMSON REUTERS
·
16 Jan

BTIG Initiates ImmunityBio at Buy With $6 Price Target

MT Newswires Live
·
10 Jan

Immunitybio Inc : Btig Initiates Coverage With Buy Rating; Target Price $6

THOMSON REUTERS
·
10 Jan

ImmunityBio initiated with a Buy at BTIG

TIPRANKS
·
10 Jan

Pfizer's bladder cancer therapy meets main goal in late-stage study

Reuters
·
10 Jan